Epizyme, Inc. (EPZM)

[02opida]

UPDATE: H.C. Wainwright & Co. Initiates Coverage On Epizyme, Transition Therapeutics
11:22a ET July 15, 2014 (Benzinga) Print


In a note released Tuesday morning, H.C. Wainwright analyst Andrew Fein initiated a Buy on both Epizyme (NASDAQ: EPZM) and Transition Therapeutics (NASDAQ: TTHI) and set respective price targets of $40 and $10.

Epizyme
Amid the transition of big pharma from genetics to epigenetics, Fein likes Epizyme's platform pipeline, technology expertise and market position in the histone methyltransferase space.

Fein noted that the company has around $240 million in cash-on-hand, which he expects will fund Epizyme's operations through 2016.

"We believe that EPZM shares will perform well in next six months as preclinical and mechanistic updates first grab and then focus investor attention in anticipation of value-driving clinical data from EPZ-5676 and EPZ-6438," wrote Fein.